Calmark announces outcome of warrant exercise
During the period 23 May – 13 June 2019, holders of subscription warrants for Series TO 1 B in Calmark Sweden AB (publ) ("Calmark) have been entitled to subscribe for shares with warrants. A total of 2 487 202 Series TO 1 B subscription warrants were exercised, corresponding to 2 487 202 B shares and an overall exercise rate of approximately 83 percent. Calmark will thus receive approximately MSEK 13.4 in proceeds from the warrant exercises, before transaction costs of approximately MSEK 0.9. Sedermera Fondkommission has acted as financial advisor in connection with the exercise period.
Number of shares and share capital
Calmark receives approximately MSEK 13.4 in proceeds, before transaction costs. The transaction costs are estimated to be approximately MSEK 0.9, corresponding to approximately 6.7 percent of the issue volume in the company's exercise of warrants. Once the new shares have been registered with the Swedish Companies Registration Office, the number of shares in Calmark will amount to 12 891 707 shares, and the share capital will amount to approximately SEK 1 289 170.20.
Anna Söderlund, CEO, comments:
”We would like to express our deep gratitude to everyone who has participated in the warrant exercise, and who will now be joining us on our journey, to help us give newborns a better start in life by facilitating diagnosis and streamlining the chain of care. We are now looking forward to exciting months ahead, and to our planned market launch in early 2020".
Sedermera Fondkommission is the financial advisor and issuing agent of Calmark in connection with the exercise period for the company’s Series TO 1 B subscription warrants.
For more information regarding the subscription of Series TO 1 B subscription warrants, please contact:
Telephone: +46 40-615 14 10
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 213 25 35
Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analyzis method with easier and faster sampling of medical conditions in newborns. The unique test platform, which consists of a reader and single-use products, is expected to be ready for launch in 2020 when three important POC tests are introduced. The WHO estimates that 1.5 billion children will be born worldwide by 2030. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter healthcare chains. In less developed healthcare systems, the product helps save lives. Calmark aims to become the global leader and ultimately to offer all relevant POC tests for the first period of life, regardless of where in the world a baby is born. Read more about Calmark www.calmark.se/eng/home.